T

The University of Hong Kong | Department of Medicine

Research site
(Unclaimed)
Location
Pok Fu Lam, Room 809, Hong Kong, Guangdong, China
Site insights

Top conditions

Hepatitis B (8 trials)

Dental Caries (8 trials)

Hepatitis (8 trials)

Hepatitis A (7 trials)

COVID-19 (7 trials)

Top treatments

Propofol
Dexamethasone
Bupivacaine
Cisplatin
Silver Diamine Fluoride
AgNO3
Fluoride
Pembrolizumab
Avelumab
Platinum

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 239
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET)...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Osimertinib
Drug: Tepotinib

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting
Immunoglobulin A Nephropathy
IgA Nephropathy
Drug: Placebo
Drug: Atrasentan

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor...

Active, not recruiting
Breast Cancer
Melanoma
Drug: Entrectinib

The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients wil...

Active, not recruiting
Advanced or Metastatic Solid Tumor
Myeloid or Lymphoid Neoplasms (MLN)
Drug: Futibatinib

The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: M7824

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-...

Enrolling
Triple Negative Breast Cancer
Biological: adagloxad simolenin combined with OBI-821
Other: Standard of care treatment

Trial sponsors

The University of Hong Kong (HKU) logo

The University of Hong Kong (HKU) (212 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems